

Early Diagnosis Crucial for Bowel Cancer Survival

Bowel cancer is the UK's second biggest cancer killer; however, it shouldn't be because it is treatable and curable, especially when diagnosed early.

CANTERBURY, KENT, UNITED KINGDOM, April 10, 2019 /EINPresswire.com/ -- Bowel cancer is the UK's second biggest cancer killer; however, it shouldn't be because it is treatable and curable, especially when diagnosed early. Nearly everyone diagnosed at the earliest stage will survive bowel cancer, but this drops significantly as the disease develops.

April is Bowel Cancer Awareness Month (BCAM), supporting fundraising and raising awareness of the mission

Cancer attacking bowel cells of Bowel Cancer UK to ensure that by 2050, no-one will die of the disease. Follow the hashtag The sooner bowel cancer is diagnosed the easier it is to



#thisishowelcancer.

Like most diseases, early diagnosis can mean early treatment, which is especially important in the case of bowel cancer" Wesley Baker - CEO of ANCON Medical treat, but currently, no available screening test has proven to be 100 per cent accurate. Tests such as a colonoscopy or flexible sigmoidoscopy are currently key diagnostics for bowel cancer but sadly, the invasive nature of these tests deters many from coming forward.

This is why early detection using non-invasive devices like ANCON Medical's NBT can be crucial in treatment. Simple to use and highly sensitive, the Nanoparticle Biomarker Tagging (NBT) device can detect the presence of a disease

by measuring exhaled breath for "biomarkers" which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases.

"Like most diseases, early diagnosis can mean early treatment, which is especially important in the case of bowel cancer," said ANCON Medical CEO Wesley Baker. "Shining a light on these sometimes-overlooked diseases not only creates awareness of the conditions, but it also reminds people of the importance of getting screened."

Researchers have discovered biomarkers for more than 400 diseases, with Bowel and other cancers among those.

"Being programmable makes an ANCON's NBT device quite versatile. It can be used to screen for diseases like cancer and later be reprogrammed to test for a range of other diseases when

needed," Baker, a member of the Royal Society of Medicine said. "Lung Cancer, Influenza, Cervical Cancer, the Ebola virus, Tuberculosis and COPD (chronic obstructive pulmonary disease) are just some of the diseases where known biomarkers have been discovered."

For more information on Bowel Cancer symptoms and what to do, visit https://www.bowelcanceruk.org.uk

For more information on ANCON Medical's NBT technology, visit https://anconmedical.com/nbt-technology

Joanna Stephens ANCON Medical +44 1227 811705 email us here



Wesley Baker - CEO ANCON Medical



ANCON Team in Canterbury

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.